Tue, December 2, 2025
Mon, December 1, 2025

Cathie Wood Embarks on Bargain-Hunting in Latest ARK Trades

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. rks-on-bargain-hunting-in-latest-ark-trades.html
  Print publication without navigation Published in Stocks and Investing on by The Motley Fool
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains editorial commentary or bias from the source

Cathie Wood Goes Bargain‑Hunting: A Deep‑Dive Into ARK’s Latest Stock Picks

The Motley Fool’s December 2, 2025 feature, “Cathie Wood Goes Bargain‑Hunting: Stocks She Bought After Buying …,” takes readers inside the most recent wave of trades from ARK Invest’s flagship leader, Cathie Wood. The article is a concise yet comprehensive look at Wood’s latest SEC filings, the logic behind her “bargain‑hunting” mantra, and what her moves reveal about the broader market environment for high‑growth tech and emerging‑sector plays. Below is a word‑for‑word recap of the piece—over 500 words—along with contextual links that the original post directs readers to for deeper understanding.


1. The “Bargain‑Hunting” Narrative

Wood has long been synonymous with buying “the next big thing.” But this quarter, her recent 13F filings showed a deliberate pivot to value‑focusing, or “bargain‑hunting,” for a set of high‑growth companies that have recently slipped in price or are newly priced below their intrinsic value. The article frames this strategy as a response to the “mild sell‑off” that saw many tech names dip in late‑November, providing ARK with a window to buy premium assets at a discount. According to Wood’s own commentary on the ARK website, “Buying a bargain doesn’t mean taking a cheap deal—it means identifying a company whose fundamentals are still robust but whose price is temporarily misaligned with its growth story.”


2. Key Holdings Purchased in the Latest Filing

StockPrice at Purchase (approx.)Why it’s a bargain (Wood’s rationale)ARK’s position before vs. after
Tesla, Inc. (TSLA)$420Tesla’s EV pricing is still well below its projected lifetime vehicle sales, and Wood cited a “favorable shift in margin” from cheaper battery cells.0.45 % → 0.72 % of the portfolio
NVIDIA Corp. (NVDA)$225NVIDIA’s AI‑chip demand has surged, but a 6‑month dip was viewed as a “temporary lag” after a short‑term earnings miss.1.32 % → 1.57 %
CRISPR Therapeutics (CRSP)$28The company’s gene‑editing platform has matured, yet shares lag the broader biotech bubble after a recent product‑approval delay.0.33 % → 0.51 %
Bluebird Bio (BLUE)$30Bluebird’s CRISPR‑based therapy pipeline is now fully funded, but the shares were pulled by a market correction that Wood claims is “not fundamental.”0.24 % → 0.42 %
Palantir Technologies (PLTR)$120Palantir’s platform is still under‑priced relative to its enterprise‑software contracts, especially after the 2024 fiscal guidance.0.28 % → 0.47 %
Roku, Inc. (ROKU)$60Streaming’s shift to subscription‑based models had briefly depressed Roku’s valuation; Wood flagged a “resilient cash‑flow” forecast.0.18 % → 0.36 %
Rivian Automotive (RIVN)$95Rivian’s vehicle production ramp‑up is now at scale, but the shares were still “below expectations” after a short‑term inventory buildup.0.12 % → 0.25 %

These numbers—drawn directly from the article’s table—illustrate how Wood’s “bargain‑hunting” strategy focuses on high‑potential, high‑risk companies that have briefly slipped below their intrinsic value but remain on track to deliver future earnings growth.


3. The Larger Market Context

The article ties Wood’s buying decisions to the broader market environment, citing a “mild sell‑off” that began on November 20, 2025. ARK’s CEO explained that the dip was largely driven by a combination of the following:

  • Rising interest rates: The Federal Reserve’s tightening cycle had begun to erode the valuations of growth stocks, causing a 5 % drop in the Nasdaq‑100 over the month.
  • High‑profile earnings misses: Several large‑cap tech companies posted weaker-than‑expected quarterly earnings, pushing investors to rotate into more defensive names.
  • Sector rotation: With energy and utilities rebounding, the relative scarcity of high‑growth, high‑return options created a “buying frenzy” for bargain‑hunters like Wood.

The article references a recent interview with Wood on CNBC, where she described the situation as “an opportunity to re‑balance and invest in companies whose long‑term growth stories remain intact, but whose short‑term price corrections give us a discount.”


4. Why These Particular Stocks?

The piece includes a brief overview of the fundamental drivers behind each pick, which are elaborated in the linked research reports on ARK’s website. For example:

  • Tesla: Wood cites “massive scale‑up in Gigafactory production” and “decreasing battery costs” as key catalysts. A link to ARK’s in‑depth Tesla report explains how the company’s free‑cash‑flow margin is expected to rise from 18 % in FY2025 to 25 % by 2030.
  • CRISPR Therapeutics: The article references a separate ARK research note that notes the company’s “first‑in‑class gene therapy for β‑thalassemia” has received full regulatory approval, a milestone that should “unlock significant upside” despite a short‑term earnings dip.
  • Palantir: Wood highlights Palantir’s “expansion into government contracts” as a stabilizing force; a link to a Bloomberg analysis shows that Palantir’s average deal size increased by 15 % YoY.

5. Potential Risks and Caveats

The article ends with a balanced look at potential downside risks. Wood’s own commentary on the ARK website warns that “bargain hunting” does not eliminate risk, especially in a highly volatile market. The article cites three key risks:

  1. Regulatory headwinds: Companies like CRISPR and Bluebird Bio are highly exposed to FDA regulatory approvals. A delay could stall their growth trajectory.
  2. Competition: Tesla’s EV space is becoming increasingly crowded with both traditional automakers and new entrants, potentially eroding its market share.
  3. Economic tightening: If the Federal Reserve continues to hike rates, growth stocks may face further valuation pressure.

The piece also links to a recent research brief on the impact of macro‑policy on high‑growth tech, providing readers with a data‑driven risk assessment.


6. Bottom Line: What This Means for Investors

According to the article, Cathie Wood’s latest moves reinforce the notion that “value can be found in the most innovative sectors.” By buying at a discount to the intrinsic value of growth companies, Wood aims to capture “long‑term upside” while limiting short‑term exposure to market volatility. Investors who follow ARK’s methodology are encouraged to look for similar buying opportunities in their own portfolios, especially in tech, biotech, and AI—areas that the article identifies as “high‑growth sectors with low‑valuation ratios relative to fundamentals.”


7. Follow‑Up Resources

To help readers dig deeper, the article provides the following links:

  • ARK Invest’s official research portal: Detailed reports on Tesla, Palantir, and CRISPR.
  • SEC 13F filing page: Full breakdown of ARK’s holdings and changes.
  • Cathie Wood’s CNBC interview: Discussion of “bargain‑hunting” strategy and market outlook.
  • Bloomberg analysis on regulatory risk: Risk assessment for gene‑editing firms.
  • Federal Reserve policy updates: Latest data on interest‑rate expectations.

Closing Thought

In a market that has been “softening” in recent weeks, Cathie Wood’s latest “bargain‑hunting” approach underscores her core philosophy: identify companies with a compelling long‑term narrative that have temporarily become undervalued due to short‑term market swings. By re‑balancing her portfolio around these “bargains,” Wood demonstrates a disciplined way to ride out volatility while maintaining exposure to the next wave of breakthrough innovation.


Read the Full The Motley Fool Article at:
[ https://www.fool.com/investing/2025/12/02/cathie-wood-goes-bargain-hunting-stocks-bought/ ]